Streetbeat News

Analyst Ratings

HTGC

Compass Point analyst Casey Alexander has downgraded Hercules Capital (NYSE:HTGC) from Buy to Neutral and set a price target of $17.5.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 8:00 pm

VTR

Ventas (NYSE:VTR) has been analyzed by 4 analysts, showing a positive trend with 2 bullish and 2 somewhat bullish ratings. The average 12-month price target is $51.75, up from the previous $48.50. Analysts from B of A Securities, Mizuho, Wells Fargo, and Wedbush have adjusted their price targets, with the highest being $56.00 and the lowest at $47.00. Ventas's financials show a strong market presence with a market cap above industry benchmarks, impressive revenue growth of 10.85%, but challenges in profitability and asset utilization with a net margin of -6.19% and ROA of -0.28%.

Portfolio Pulse from Benzinga Insights

January 16, 2024 | 8:00 pm

TXN

Texas Instruments (NASDAQ:TXN) received 19 analyst ratings over the last three months with diverse outlooks. The average 12-month price target is now $167.16, a 7.85% decrease from the previous $181.40. Analysts from firms like Barclays, Truist Securities, and BMO Capital have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Texas Instruments, a major semiconductor manufacturer, faces revenue challenges with a -13.53% decline over 3 months but maintains strong profitability with a net margin of 37.51% and excels in ROE and ROA. However, it has a high debt-to-equity ratio of 0.67.

Portfolio Pulse from Benzinga Insights

January 16, 2024 | 8:00 pm

CVI

Scotiabank analyst Paul Cheng downgraded CVR Energy (NYSE:CVI) from Sector Perform to Sector Underperform and reduced the price target from $28 to $25.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 7:58 pm

CVX

Scotiabank analyst Paul Cheng downgraded Chevron (NYSE:CVX) from Sector Outperform to Sector Perform and set a price target of $170.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 7:56 pm

APA

Scotiabank analyst Paul Cheng downgraded APA Corporation from Sector Outperform to Sector Perform and reduced the price target from $43 to $37.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 7:50 pm

HARP

TD Cowen analyst Tara Bancroft has downgraded Harpoon Therapeutics (NASDAQ:HARP) from Outperform to Market Perform, indicating a change in the stock's expected performance.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 7:49 pm

NAMS

Piper Sandler initiated coverage on NewAmsterdam Pharma Co. NV (NASDAQ:NAMS) with an Overweight rating and a price target of $37. The company's lead asset, obicetrapib, is a novel CETP inhibitor targeting the cardiovascular market, with potential to be a blockbuster due to the large patient population requiring lipid-lowering treatments. NewAmsterdam is poised for three Phase 3 trial readouts over the next 18 months, with significant growth expected in the non-statin treatment market.

Portfolio Pulse from Vandana Singh

January 16, 2024 | 7:48 pm

BOOT

Williams Trading analyst Sam Poser has downgraded Boot Barn Holdings (NYSE:BOOT) from Buy to Hold, indicating a shift in their outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 7:47 pm

FIVE

Craig-Hallum analyst Jeremy Hamblin has downgraded the stock of Five Below (NASDAQ:FIVE) from Buy to Hold.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 7:46 pm